Inovio Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1979-01-01
- Employees
- 122
- Market Cap
- $192.9M
- Website
- http://www.inovio.com
- Introduction
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
Clinical Trials
56
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (55 trials with phase data)• Click on a phase to view related trials
Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
- Conditions
- Coronavirus Infection
- Interventions
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Inovio Pharmaceuticals
- Registration Number
- NCT05430958
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
- Conditions
- Coronavirus InfectionSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)COVID-19 Disease
- Interventions
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Inovio Pharmaceuticals
- Target Recruit Count
- 1307
- Registration Number
- NCT04642638
- Locations
- 🇺🇸
Synexus Clinical Research US, Inc - Phoenix Southeast, Chandler, Arizona, United States
🇺🇸Central Phoenix Synexus Clinical Research, Phoenix, Arizona, United States
🇺🇸AMR Tempe, Tempe, Arizona, United States
Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
- Conditions
- Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Inovio Pharmaceuticals
- Target Recruit Count
- 192
- Registration Number
- NCT04588428
- Locations
- 🇯🇴
Clinical Research Center, Irbid Specialty Hospital (CRC/ISH), Irbid, Jordan
🇯🇴Pharmaceutical Research Center / Jordan University of Science and Technology, Irbid, Jordan
🇰🇪Kenya Medical Research Institute (KEMRI)/Walter Reed Project (WRP), Kericho, Kenya
INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
- Conditions
- Respiratory Papillomatosis
- Interventions
- Device: CELLECTRA™ 2000
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Inovio Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT04398433
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸University of California at Davis, Sacramento, California, United States
🇺🇸Winship at Emory University Hospital Midtown, Atlanta, Georgia, United States
Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Inovio Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT04336410
- Locations
- 🇺🇸
Central Kentucky Research Associates, Lexington, Kentucky, United States
🇺🇸Center for Pharmaceutical Research, Kansas City, Missouri, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
Avacta Strengthens Leadership Team with Appointment of Chief Medical Officer and Business Development Advisor
Avacta Group plc has appointed David Liebowitz, M.D., Ph.D. as Chief Medical Officer to lead clinical strategy and execution for its targeted cancer therapy pipeline.
Three Pharmaceutical Companies Advance Next-Generation COVID-19 Therapeutics in Clinical Trials
INOVIO Pharmaceuticals reports promising Phase I results for its DMAbs technology, showing 100% of subjects maintained relevant antibody levels with no serious adverse events.
Needle-Free Drug Delivery Devices Market Set to Reach $5+ Billion by 2035
The needle-free injection system market is projected to grow at a CAGR of 4% from $606 million in 2024 to 2035, driven by increasing chronic disease prevalence and patient preference for painless administration.
Former GSK CEO Sir Andrew Witty Appointed to Lead WHO's Global COVID-19 Vaccine Initiative
• Sir Andrew Witty, former GlaxoSmithKline CEO, takes temporary leave from UnitedHealth's Optum to spearhead WHO's COVID-19 vaccine development efforts starting next week. • Over 70 COVID-19 vaccine candidates are in development globally, with three frontrunners from CanSino Bio, Moderna, and Inovio already advancing to clinical testing phases. • The appointment comes at a critical time as WHO faces funding challenges, with the Gates Foundation pledging $150 million following US funding withdrawal.
AstraZeneca Expands Immuno-Oncology Portfolio with Three Strategic Partnerships
• AstraZeneca secures rights to Inovio's INO-3112, a DNA vaccine targeting HPV-related cancers, in a deal worth up to $727.5 million, planning combination studies with durvalumab. • MedImmune partners with Heptares on adenosine A2A receptor antagonist HTL-2071 for $510 million, aiming to enhance T-cell anti-cancer activity. • A collaboration with Mirati Therapeutics will explore combining durvalumab with HDAC inhibitor mocetinostat in non-small cell lung cancer trials starting next year.